Teleflex Wins New Zealand Innovation Award for UroLift System for Patients with Enlarged Prostate
August 07 2019 - 6:45AM
Teleflex Incorporated (NYSE: TFX) today announced the
UroLift® System, a proven, minimally invasive treatment for
patients with benign prostatic hyperplasia (BPH), won the 2019
James & Wells Medical Technology Association of New Zealand
(MTANZ) Innovation Award at the Health Tech Week Gala on July 2.
The MTANZ Innovation Award recognizes products that significantly
contribute to improving patient outcomes by enhancing their quality
of life, as well as exhibiting technical excellence and innovation
across the entire medical device sector. Recipients for the MTANZ
Innovation Award are determined by a judging panel consisting of
distinguished industry leaders and clinicians.
“We are thrilled to be recognized by MTANZ and
the medical technology community as the 2019 Innovation Award
winner for the UroLift System and the positive impact the treatment
has had on patients suffering from the burdensome symptoms of BPH,”
said Dave Amerson, president of Teleflex Interventional Urology
business unit. “We look forward to continuing to treat more New
Zealand patients with the UroLift System, so they can achieve rapid
and lasting symptom relief and return to a better quality of
life.”
BPH, also known as enlarged prostate, is
non-cancerous enlargement of the prostate that occurs as men age.
The condition affects over 40 million men in the United States
alone, with more than 40% of men in their 50s have BPH and over 80%
of men in their 70s have BPH. The symptoms of BPH can cause loss of
productivity, depression and decreased quality of life.1 In
addition, if left untreated the condition can worsen over time and
cause permanent bladder damage.2
The UroLift System is a minimally invasive
approach to treating enlarged prostate that may allow men to get
off BPH medications and avoid major surgery, while also providing
rapid symptom relief and recovery with results in days rather than
months.2,3 The Prostatic Urethral Lift procedure is recommended for
the treatment of BPH in both the American Urological Association
and European Association of Urology clinical guidelines.
About the
UroLift® SystemThe FDA-cleared UroLift System is a
proven, minimally invasive technology for treating lower urinary
tract symptoms due to benign prostatic hyperplasia (BPH). The
UroLift permanent implants, delivered during a minimally invasive
transurethral outpatient procedure, relieve prostate obstruction
and open the urethra directly without cutting, heating, or removing
prostate tissue. Clinical data from a pivotal 206-patient
randomized controlled study showed that patients with enlarged
prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function.*3 Patients also experienced significant
improvement in quality of life. Over 100,000 men have been treated
with the UroLift System worldwide. Most common adverse events
reported include hematuria, dysuria, micturition urgency, pelvic
pain, and urge incontinence. Most symptoms were mild to moderate in
severity and resolved within two to four weeks after the
procedure.
The Prostatic Urethral Lift procedure using the
UroLift System is recommended for the treatment of BPH in both the
American Urological Association and European Association of Urology
clinical guidelines. The UroLift System is available in the U.S.,
Europe, Australia, Canada, Mexico, New Zealand and South Korea.
Learn more at www.UroLift.com.
About Teleflex Interventional
UrologyThe Teleflex Interventional Urology Business Unit
is dedicated to developing innovative, minimally invasive and
clinically effective devices that address unmet needs in the field
of urology. Our initial focus is on improving the standard of care
for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while
preserving normal sexual function.*3 Learn more
at www.NeoTract.com.
About Teleflex
IncorporatedTeleflex is a global provider of medical
technologies designed to improve the health and quality of people’s
lives. We apply purpose driven innovation – a relentless pursuit of
identifying unmet clinical needs – to benefit patients and
healthcare providers. Our portfolio is diverse, with solutions in
the fields of vascular and interventional access, surgical,
anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®,
Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® –
trusted brands united by a common sense of purpose.
# # #
Contacts:
For Teleflex Incorporated:Jake Elguicze,
610.948.2836Treasurer and Vice President, Investor Relations
Media:Nicole Osmer,
650.454.0504nicole@healthandcommerce.com
1. Speakman et al. 2014 BJUI
International 2. Tubaro et al. 2003 Drugs Aging 3. Roehrborn,
J Urology 2013 LIFT Study*No instances of new, sustained erectile
or ejaculatory dysfunction
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024